PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple sclerosis |
| Symptom | C0030193|pain |
| Sentences | 40 |
| PubMedID- 23288696 | Effects of topiramate on dysaesthetic pain in a patient with multiple sclerosis. |
| PubMedID- 26087108 | The prevalence of pain in adults with multiple sclerosis: a multicenter cross-sectional survey. |
| PubMedID- 22330129 | pain in individuals with multiple sclerosis, knee prosthesis, and post-herpetic neuralgia: learning from focus group patients' experience. |
| PubMedID- 20236042 | Cannabinoids have been used in the treatment of nausea and emesis, anorexia and cachexia, tremor and pain associated with multiple sclerosis. |
| PubMedID- 25000215 | Each study included participants with a different type of neuropathic pain; central pain due to multiple sclerosis, pain following spinal cord injury, painful polyneuropathy, central post-stroke pain, postherpetic neuralgia, and post-mastectomy pain.none of the included studies provided first or second tier evidence. |
| PubMedID- 20568832 | Pharmacological management of pain in patients with multiple sclerosis. |
| PubMedID- 26543389 | In addition, analgesic properties of cannabinoids are advanced in some cannabis sativa plant extracts for adjunctive treatment of neuropathic pain in patients with multiple sclerosis. |
| PubMedID- 24179780 | Dti detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis. |
| PubMedID- 20806080 | In addition, cbd has been approved for the treatment of inflammation, pain, and spasticity associated with multiple sclerosis in humans (reviewed in ). |
| PubMedID- 23180178 | A double-blind, randomized, placebo-controlled, parallel-group study of thc/cbd oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. |
| PubMedID- 22629287 | Recent clinical trials with smoked and vaporized marijuana, as well as other botanical extracts indicate the likelihood that the cannabinoids can be useful in the management of neuropathic pain, spasticity due to multiple sclerosis, and possibly other indications. |
| PubMedID- 23137071 | The association of depression with pain-related treatment utilization in patients with multiple sclerosis. |
| PubMedID- 23837007 | It has recently been shown that anodal tdcs resulted in large positive effects on neuropathic pain due to multiple sclerosis, with long duration of the after-effect.23 it would be of interest to compare the effects of tdcs and trns in double-blind crossover studies. |
| PubMedID- 24152240 | A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. |
| PubMedID- 24525905 | Widespread pressure pain hypersensitivity in patients with multiple sclerosis with and without pain as sign of central sensitization. |
| PubMedID- 20018567 | Effects of anodal transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis. |
| PubMedID- 22925457 | Objective: to identify empirically derived cutoffs for mild, moderate, and severe pain in persons with multiple sclerosis (ms). |
| PubMedID- 26480924 | Objective: we prospectively assessed the prevalence of neuropathic pain in patients with early multiple sclerosis and investigated the association of neuropathic pain with other clinical parameters. |
| PubMedID- 21918649 | More recently, pilot trials of low-dose naltrexone hydrochloride (ldn), which is a pharmaceutical similar to naloxone, have recently gained increasing recognition for treating chronic pain associated with fibromyalgia, multiple sclerosis, and crohn's disease . |
| PubMedID- 22739983 | Cbd has been approved to treat inflammation, pain and spasticity associated with multiple sclerosis (ms), of which demyelination and oligodendrocyte loss are hallmarks. |
| PubMedID- 22851976 | Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline. |
| PubMedID- 21887119 | pain in patients with multiple sclerosis: a complex assessment including quantitative and qualitative measurements provides for a disease-related biopsychosocial pain model. |
| PubMedID- 24093124 | Does pain in individuals with multiple sclerosis affect employment. |
| PubMedID- 24347834 | Focused on neuropathic pain, associated with multiple sclerosis and guillain-barre syndrome, as well as with experimental autoimmune encephalomyelitis and experimental autoimmune neuritis, in animal models which enable investigations of behavioural changes, underlying mechanisms, and potential pharmacotherapeutic approaches for neuropathic pain, associated with these diseases. |
| PubMedID- 25112815 | Background: pain affects around 63% of people with multiple sclerosis (pwms). |
| PubMedID- 23621668 | Introduction: pain associated with multiple sclerosis (ms) is frequent, and frequently not alleviated by currently available drugs. |
| PubMedID- 26008938 | Systematic review of efficacy of tens for management of central pain in people with multiple sclerosis. |
| PubMedID- 24742132 | This is to our knowledge the first detailed report of a case with an exacerbation of symptomatic trigeminal neuralgia in parallel to the onset of an immunomodulatory treatment for ms. painful trigeminal neuropathy attributed to a multiple sclerosis plaque is defined by ichd-3 beta criteria as pain clinically similar to classical trigeminal neuralgia 2. |
| PubMedID- 21785645 | Hydrotherapy for the treatment of pain in people with multiple sclerosis: a randomized controlled trial. |
| PubMedID- 22014239 | Its use is also increasingly recognized in the treatment of a range of diseases such as multiple sclerosis and conditions with chronic pain . |
| PubMedID- 22301508 | In this case report, a 61-year-old woman with chronic central neuropathic pain due to multiple sclerosis is described. |
| PubMedID- 24648785 | Given the therapeutic potential of cannabinoids such as δ9-thc in the management of medical conditions including neuropathic pain or spasticity due to multiple sclerosis (for a review see grant et al146), an understanding of the neural mechanisms underlying the effects of cannabis on memory function also has a wider implication beyond psychiatric disorders, as it may lead to the identification or synthesis of related molecules with the desired therapeutic effects, but without the undesired side effects. |
| PubMedID- 24621986 | The aim of this paper was to evaluate non-pharmacological strategies for the reduction of non-spastic and non-trigeminal pain in patients with multiple sclerosis (ms) by conducting a systematic review. |
| PubMedID- 20649467 | Central neuropathic pain occurs with multiple sclerosis, stroke, and spinal cord injury (sci). |
| PubMedID- 23318126 | Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. |
| PubMedID- 21642854 | Cognitive-behavioral classifications of chronic pain in patients with multiple sclerosis. |
| PubMedID- 24757491 | It also showed potency in reducing neuropathic pain and slowing progression of atherosclerosis and multiple sclerosis models in rats. |
| PubMedID- 26177836 | Background and purpose: pain affects around two-thirds of people with multiple sclerosis (pwms). |
| PubMedID- 23615703 | Longitudinal 7-year follow-up of chronic pain in persons with multiple sclerosis in the community. |
| PubMedID- 21144973 | Background: cannabidiol, the most abundant nonpsychoactive constituent of cannabis sativa (marijuana) plant, exerts anti-inflammatory effects in various disease models and alleviates pain and spasticity associated with multiple sclerosis in humans. |
Page: 1